Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting

Autor: Puente, J, Grande, E, Medina, A, Maroto, P, Lainez, N, Arranz, JA

Publikováno v: Therapeutic Advances in Medical Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

The increasing knowledge of prostate cancer is leading to many questions about its natural history and to reconsider conventional therapeutic strategies. Androgen ablation therapy has been the standard therapy in the advanced setting. Although doceta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::9db7378403121a9fba4f0220fb508a57
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6463

Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting.

Autor: Puente J; Medical Oncology Department, Hospital Clínico Universitario San Carlos, C/ Profesor Martín Lagos, S/N, 28040 Madrid, Spain., Grande E; Hospital Universitario Ramón y Cajal, Madrid, Spain., Medina A; Centro Oncológico de Galicia, A Coruña, Spain., Maroto P; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Lainez N; Hospital de Navarra, Pamplona, Spain., Arranz JA; Hospital Gregorio Marañon, Madrid, Spain.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2017 May; Vol. 9 (5), pp. 307-318. Date of Electronic Publication: 2017 Mar 01.